Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...
CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...
The anti-tumor immune response involves a series of complex steps mediated by various immune cells and signaling molecules.
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Eureka Therapeutics, Inc., a clinical-stage biotechnology company advancing next-generation T-cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Unlike patients with HER2+ tumors, there is an unmet clinical need for patients with HER2-low expression cancers, which are refractory to trastuzumab. Sanofi SA has developed TPP-45142, a T-cell ...
Detailed price information for Tscan Therapeutics Inc (TCRX-Q) from The Globe and Mail including charting and trades.
Immunocore is expanding its ImmTAX platform into autoimmune disease, outlining plans to start first‑in‑human trials of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results